Mescheriakova Julia Y, Broer Linda, Wahedi Simin, Uitterlinden André G, van Duijn Cornelia M, Hintzen Rogier Q
Department of Neurology, Erasmus Medical Centre, the Netherlands.
Mult Scler J Exp Transl Clin. 2016 May 6;2:2055217316648721. doi: 10.1177/2055217316648721. eCollection 2016 Jan-Dec.
Approximately 20% of multiple sclerosis patients have a family history of multiple sclerosis. Studies of multiple sclerosis aggregation in families are inconclusive.
To investigate the genetic burden based on currently discovered genetic variants for multiple sclerosis risk in patients from Dutch multiple sclerosis multiplex families versus sporadic multiple sclerosis cases, and to study its influence on clinical phenotype and disease prediction.
Our study population consisted of 283 sporadic multiple sclerosis cases, 169 probands from multiplex families and 2028 controls. A weighted genetic risk score based on 102 non-human leukocyte antigen loci and was calculated.
The weighted genetic risk score based on all loci was significantly higher in familial than in sporadic cases. The contributed significantly to the difference in genetic burden between the groups. A high weighted genetic risk score was significantly associated with a low age of disease onset in all multiple sclerosis patients, but not in the familial cases separately. The genetic risk score was significantly but modestly better in discriminating familial versus sporadic multiple sclerosis from controls.
Familial multiple sclerosis patients are more loaded with the common genetic variants than sporadic cases. The difference is mainly driven by . The predictive capacity of genetic loci is poor and unlikely to be useful in clinical settings.
约20%的多发性硬化症患者有多发性硬化症家族史。关于多发性硬化症在家族中的聚集性研究尚无定论。
基于目前发现的与荷兰多发性硬化症多重家庭患者和散发性多发性硬化症病例患多发性硬化症风险相关的基因变异,研究遗传负担,并探讨其对临床表型和疾病预测的影响。
我们的研究人群包括283例散发性多发性硬化症病例、169例多重家庭的先证者和2028名对照。计算了基于102个非人类白细胞抗原基因座的加权遗传风险评分。
基于所有基因座的加权遗传风险评分在家族性病例中显著高于散发性病例。 对两组间遗传负担的差异有显著贡献。在所有多发性硬化症患者中,高加权遗传风险评分与低发病年龄显著相关,但在家族性病例中无此关联。在区分家族性和散发性多发性硬化症与对照方面,遗传风险评分有显著但适度的改善。
家族性多发性硬化症患者比散发性病例携带更多常见基因变异。这种差异主要由 驱动。基因座的预测能力较差,不太可能在临床环境中发挥作用。